Adaptive Biotechnologies Corporation (ADPT) Bundle
A Brief History of Adaptive Biotechnologies Corporation (ADPT)
Foundation and Early Development
Foundation and Early Development
Adaptive Biotechnologies was founded in 2009 by Harlan Robins and Chris W. McDonald in Seattle, Washington. The company was established with the objective of harnessing the adaptive immune system to develop transformative therapies for diseases.
Initial Funding and Growth
In its early years, Adaptive Biotechnologies secured venture capital funding. By 2015, the company had raised around $250 million from investors, including Viking Global Investors, OrbiMed Advisors, and Foresite Capital.
Development of Technology Platforms
The company's proprietary Adaptive TCR (T-cell receptor) sequencing technology allows for the analysis of T-cell receptors in detail. This technology plays a crucial role in developing therapies for various diseases, especially cancer.
Partnerships and Collaborations
In 2016, Adaptive Biotechnologies entered into a significant collaboration with Amgen focused on advancing the development of T-cell based therapies. This partnership was part of a broader strategy to leverage academic research and pharmaceutical know-how.
Public Offering and Market Performance
Adaptive Biotechnologies went public on June 4, 2019, with an initial public offering (IPO) price of $20 per share, raising approximately $300 million. The stock was listed on NASDAQ under the ticker symbol ADPT.
As of October 2023, ADPT shares have experienced fluctuations, reaching a market capitalization of approximately $1.2 billion.
Recent Developments and Financial Performance
In the fiscal year 2022, Adaptive Biotechnologies reported total revenues of approximately $138 million, a significant increase from $92 million in 2021. The revenue growth was primarily driven by increased demand for its diagnostic tests, particularly clonoSEQ, which is used for monitoring minimal residual disease in blood cancers.
Financial Overview
| Year | Total Revenue ($ millions) | Net Income ($ millions) | Market Capitalization ($ billions) |
|---|---|---|---|
| 2020 | 63 | (65) | 1.1 |
| 2021 | 92 | (49) | 1.4 |
| 2022 | 138 | (87) | 1.2 |
| 2023 (Q1) | 45 | (20) | 1.2 |
Future Directions
Looking ahead, Adaptive Biotechnologies aims to expand its product offerings and enhance its platform technology, focusing on precision medicine. The company is also exploring partnerships with biotechnology and pharmaceutical firms to further its research and product development efforts.
A Who Owns Adaptive Biotechnologies Corporation (ADPT)
Major Shareholders
Adaptive Biotechnologies Corporation (ADPT) has seen significant investments from a variety of institutional and individual shareholders. As of September 2023, the top shareholders include:
| Shareholder | Type | Number of Shares | Percentage Ownership |
|---|---|---|---|
| Vanguard Group Inc. | Institutional | 4,360,000 | 10.5% |
| BlackRock Inc. | Institutional | 4,210,000 | 10.2% |
| Janus Henderson Group plc | Institutional | 3,500,000 | 8.5% |
| FMR LLC (Fidelity) | Institutional | 3,200,000 | 7.7% |
| JPMorgan Chase & Co. | Institutional | 2,800,000 | 6.5% |
Insider Ownership
Insider ownership also plays a critical role in the governance of Adaptive Biotechnologies. The following table reflects the ownership status of key executives and board members:
| Name | Position | Number of Shares | Percentage Ownership |
|---|---|---|---|
| Co-founder and CEO | Daniel Galperin | 1,200,000 | 2.9% |
| Co-founder and Chief Scientific Officer | Chad Robins | 1,500,000 | 3.6% |
| Board Member | Robert Nelsen | 800,000 | 1.9% |
| Chief Financial Officer | Seth B. Karp | 500,000 | 1.2% |
| General Counsel | Scott D. Gleason | 600,000 | 1.4% |
Institutional Investment Trends
The landscape of institutional investment in Adaptive Biotechnologies has shifted due to varying market conditions. This table illustrates the changes over the last fiscal year:
| Quarter | Institutional Ownership Percentage | Net Change (Shares) |
|---|---|---|
| Q1 2023 | 45% | -200,000 |
| Q2 2023 | 47% | +150,000 |
| Q3 2023 | 49% | +100,000 |
Stock Performance and Market Capitalization
As of September 2023, Adaptive Biotechnologies has shown a notable stock performance which impacts ownership dynamics:
| Metric | Value |
|---|---|
| Current Stock Price | $12.50 |
| Market Capitalization | $520 million |
| 52-Week High | $18.00 |
| 52-Week Low | $9.00 |
Key Takeaways
The ownership structure of Adaptive Biotechnologies Corporation reflects a mix of institutional investors and insider stakeholders, indicating a strong alignment towards the company's strategic goals. The performance of the company's stock and its market capitalization plays a significant role in shareholder value.
Adaptive Biotechnologies Corporation (ADPT) Mission Statement
Overview
Adaptive Biotechnologies Corporation, a leader in the field of immunology, aims to translate the human immune system into a powerful platform to enhance disease diagnostics and therapeutics. The mission centers on harnessing immune response data to better address various disease states, particularly in oncology and infectious diseases.
Strategic Objectives
- To develop innovative and accessible immune profiling solutions.
- To collaborate with global partners for advancing personalized medicine.
- To leverage proprietary technology to decode the immune repertoire.
- To transform patient care by providing comprehensive insights into immune responses.
Financial Data
As of Q3 2023, Adaptive Biotechnologies reported the following financial metrics:
| Metric | Value (in millions) |
|---|---|
| Revenue | $66.2 |
| Gross Profit | $38.1 |
| Net Loss | ($26.4) |
| Cash and Cash Equivalents | $120.5 |
| Research and Development Expenses | $21.0 |
Core Values
- Innovation: Fostering creativity in scientific research.
- Integrity: Upholding ethical standards in all practices.
- Collaboration: Building partnerships to enhance research outcomes.
- Patient-Centricity: Prioritizing the needs and welfare of patients.
Market Position
Adaptive Biotechnologies operates in a rapidly growing market. The global immune profiling market is projected to reach $2.5 billion by 2025, growing at a CAGR of 14.5%.
Recent Milestones
- Partnership with Microsoft for immune response data integration.
- Launch of new TCR sequencing technology in Q2 2023.
- Expansion into Europe with new testing facilities announced in July 2023.
Future Outlook
The company is focused on expanding its product offerings and enhancing its technology platform. Management forecasts a projected revenue growth of 20% for FY 2024, driven by increased adoption of its ImmuneSense product line.
How Adaptive Biotechnologies Corporation (ADPT) Works
Company Overview
Adaptive Biotechnologies Corporation (ADPT) specializes in biotechnology, focusing on the immune system. The company develops and commercializes products based on its proprietary technology platform, which decodes the adaptive immune system to diagnose and treat diseases, including cancers and autoimmune disorders.
Key Technologies
- Immune Profiling: This technology allows for a comprehensive analysis of T-cell receptors to identify immune responses.
- ClonoSeq: This is a next-generation sequencing (NGS) assay used for the detection of minimal residual disease in hematologic malignancies.
- Partnered Platforms: Adaptive collaborates with organizations like Microsoft to enhance data analysis capabilities.
Financial Performance
For the fiscal year ended December 31, 2022, Adaptive Biotechnologies reported:
| Metric | Amount (USD) |
|---|---|
| Revenue | $60.2 million |
| Net Loss | $(85.9) million |
| Research and Development Expenses | $82.4 million |
| General and Administrative Expenses | $37.8 million |
Market Position
As of Q3 2023, Adaptive Biotechnologies holds a significant position in the diagnostics market, especially within oncology, with a market share of approximately 5%. The total addressable market (TAM) for the company's products is estimated to be over $20 billion by 2025.
Partnerships and Collaborations
- Microsoft Partnership: In 2020, Adaptive partnered with Microsoft to leverage AI for immune mapping.
- Pharmaceutical Collaborations: The company has multiple collaborations for companion diagnostics, including partnerships with companies like Amgen and Novartis.
Clinical Trials and Research Development
As of October 2023, Adaptive Biotechnologies has several clinical studies underway, focusing on:
- Detection of minimal residual disease in leukemia patients.
- Identification of T-cell responses in COVID-19.
- Multiple myeloma treatment evaluation.
Stock Performance
As of October 2023, the stock price of ADPT was trading around $10.50 per share with a market capitalization of approximately $1.3 billion. The 52-week stock range has been between $8.85 and $18.00, reflecting volatility in the biotechnology sector.
Future Outlook
Following the company’s strategic plan, it anticipates growth in revenues by approximately 20% annually, driven by expanded market access and new product launches. The pipeline includes planned releases for new assays and enhancements to existing technologies.
Employee and Operational Metrics
| Metric | Number |
|---|---|
| Total Employees | Approx. 400 |
| R&D Staff | Approx. 200 |
| Sales and Marketing Staff | Approx. 100 |
Conclusion of Chapter
Adaptive Biotechnologies utilizes advanced technology to decode the immune system, aiming to revolutionize diagnostics and treatment strategies in various diseases. The company is strategically positioned for growth based on its innovative platform, clinical advancements, and strong market collaborations.
How Adaptive Biotechnologies Corporation (ADPT) Makes Money
Overview of Revenue Generation
Adaptive Biotechnologies Corporation (ADPT) generates revenue primarily through its diagnostic services and technology platforms. The company focuses on leveraging its proprietary immune profiling technology to develop diagnostic tests that enhance treatment decisions for patients with various diseases, particularly cancer and autoimmune disorders.
Diagnostic Products and Services
ADPT’s primary revenue stream comes from its diagnostic products. The company markets multiple tests that analyze T-cell receptors and B-cell receptors to provide insights for clinicians.
| Product Name | Description | Revenue (2022) | Growth Rate YoY |
|---|---|---|---|
| ClonoSeq | Test for monitoring minimal residual disease (MRD) in blood cancers | $69 million | 30% |
| T-Detect | Test for infectious diseases using T-cell receptor sequencing | $10 million | 225% |
| Immune Profiler | Comprehensive immune profiling for various diseases | $5 million | 50% |
Partnerships and Collaborations
Adaptive Biotechnologies has established partnerships with various pharmaceutical companies to enhance its product offerings. These collaborations contribute to both revenue and product development.
- Partnership with Microsoft for leveraging artificial intelligence in immune profiling
- Collaboration with Amgen to develop next-generation therapies
- Co-development agreements for clinical trials with various biotech firms
Research and Development
Investment in R&D is crucial for ADPT's long-term growth. The company allocates a significant portion of its revenue to developing new tests and improving existing technology. In 2022, ADPT spent approximately $50 million on R&D, which represents about 45% of its total operating expenses.
Financial Performance
In fiscal year 2022, Adaptive Biotechnologies reported total revenue of $151 million. The company has seen a consistent increase in revenue, driven by the growing adoption of its diagnostic services.
| Financial Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Total Revenue | $151 million | $113 million | $92 million |
| Net Income | ($76 million) | ($61 million) | ($50 million) |
| Operating Expenses | $163 million | $134 million | $112 million |
Market Trends and Future Outlook
The demand for next-generation sequencing and precision medicine continues to grow, creating a favorable market environment for ADPT. The global market for molecular diagnostics is expected to reach $25 billion by 2026, which indicates a robust growth potential for the company.
Conclusion on Revenue Streams
Adaptive Biotechnologies Corporation leverages its advanced technology in immune profiling to create diagnostic products that cater to the needs of healthcare providers and patients. The company’s focus on strategic partnerships, strong R&D investment, and market trends positions it favorably for continued growth in the diagnostics market.
Adaptive Biotechnologies Corporation (ADPT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support